"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

including Novo Nordisk's blockbuster drugs Ozempic and Saxenda. The FTC has argued that drugmakers are needlessly listing dozens of extra patents for branded medications to keep their drug prices ...

European regulators have recommended an update to the label of Novo Nordisk’s weight loss drug, Saxenda, to include information about the active ingredient’s ability to reduce cardiovascular risk.

Novo Nordisk (NVO) markets liraglutide under the brand names Victoza, Saxenda and Xultophy. The drug is currently on the FDA's drug shortage list. Compounding pharmacies are allowed to make ...

Danish pharmaceutical giant Novo Nordisk A/S (NYSE:NVO) submitted a Citizen Petition to the FDA requesting the exclusion of ...

Novo Nordisk faces scrutiny over UK pharmacy sponsorships tied to weight-loss drugs, with critics citing conflicts of interest and regulatory breaches.